دورية أكاديمية
أعرض في EDS

miR-1202 regulates BPH-1 cell proliferation, apoptosis, and epithelial-to-mesenchymal transition through targeting HMGCL.

التفاصيل البيبلوغرافية
العنوان: miR-1202 regulates BPH-1 cell proliferation, apoptosis, and epithelial-to-mesenchymal transition through targeting HMGCL.
المؤلفون: Wang Z, Yin X, Yang P, Gong B, Liu H
المصدر: Acta biochimica et biophysica Sinica [Acta Biochim Biophys Sin (Shanghai)] 2024 May 25; Vol. 56 (5), pp. 675-687.
نوع المنشور: Journal Article
اللغة: English
بيانات الدورية: Publisher: China Science Publishing & Media Ltd Country of Publication: China NLM ID: 101206716 Publication Model: Print Cited Medium: Internet ISSN: 1745-7270 (Electronic) Linking ISSN: 16729145 NLM ISO Abbreviation: Acta Biochim Biophys Sin (Shanghai) Subsets: MEDLINE
أسماء مطبوعة: Publication: 2022- : Shanghai : China Science Publishing & Media Ltd.
Original Publication: Shanghai : Shanghai Scientific and Technical Publishers, 2004-
مواضيع طبية MeSH: Apoptosis*/genetics , Apoptosis*/drug effects , Cell Proliferation*/genetics , Cell Proliferation*/drug effects , Epithelial-Mesenchymal Transition*/genetics , Epithelial-Mesenchymal Transition*/drug effects , MicroRNAs*/genetics , MicroRNAs*/metabolism , Prostatic Hyperplasia*/pathology , Prostatic Hyperplasia*/metabolism , Prostatic Hyperplasia*/genetics, Animals ; Humans ; Male ; Rats ; Cell Line ; Transforming Growth Factor beta/metabolism ; Wnt Signaling Pathway/genetics ; Wnt Signaling Pathway/drug effects
مستخلص: Benign prostatic hyperplasia (BPH) is the expansion of the prostate gland that results in urinary symptoms. Both the epithelial-to-mesenchymal transition (EMT) and the Wnt signaling pathway are associated with BPH pathology. In this study, we find that miR-1202 is increased in BPH samples. Overexpression of miR-1202 in TGF-β-treated BPH-1 cells enhances cell survival and DNA synthesis and inhibits cell apoptosis, whereas miR-1202 inhibition partially abolishes the effects of TGF-β on BPH-1 cells. miR-1202 overexpression reduces E-cadherin level but elevates vimentin, N-cadherin, and snail levels, whereas miR-1202 inhibition partially attenuates the effects of TGF-β on EMT markers. Regarding the Wnt/β-catenin pathway, miR-1202 overexpression significantly enhances, whereas miR-1202 inhibition partially decreases, the promotive effects of TGF-β on Wnt1, c-Myc, and cyclin D1 proteins. 3-Hydroxy-3-methylglutaryl-CoA lyase (HMGCL) is a direct downstream target of miR-1202, and miR-1202 inhibits HMGCL expression through binding to its 3'UTR. Overexpression of HMGCL significantly reduces the effect of miR-1202 overexpression on the phenotypes of BPH-1 cells by inhibiting cell survival and promoting apoptosis. Similarly, HMGCL overexpression has the opposite effects on EMT markers and the Wnt/β-catenin signaling, and markedly alleviates the effects of miR-1202 overexpression. Finally, in the BPH rat model, Ki67 and vimentin levels are elevated, but E-cadherin and HMGCL levels are reduced. In conclusion, miR-1202 is upregulated in benign prostatic hyperplasia; miR-1202 enhances epithelial cell proliferation, suppresses cell apoptosis, and promotes EMT by targeting HMGCL. The Wnt/β-catenin pathway may participate in the miR-1202/HMGCL axis-mediated regulation of BPH-1 cell phenotypes.
References: Cell Signal. 2021 Aug;84:110004. (PMID: 33839256)
Clin Anat. 2000;13(3):207-13. (PMID: 10797629)
Life (Basel). 2021 Oct 16;11(10):. (PMID: 34685470)
J Clin Invest. 2009 Jun;119(6):1420-8. (PMID: 19487818)
J Biol Chem. 2010 Aug 20;285(34):26341-9. (PMID: 20558737)
J Control Release. 2013 Dec 28;172(3):962-74. (PMID: 24075926)
Semin Cancer Biol. 2019 Dec;59:187-207. (PMID: 31362075)
Chin Med J (Engl). 2018 Aug 20;131(16):2008-2012. (PMID: 30082536)
Nat Cell Biol. 2017 May;19(5):518-529. (PMID: 28414315)
J Cell Physiol. 2019 Sep;234(9):14535-14555. (PMID: 30723913)
Cell. 2009 Nov 25;139(5):871-90. (PMID: 19945376)
Life Sci. 2019 Dec 1;238:116957. (PMID: 31655195)
PLoS One. 2021 Aug 24;16(8):e0256066. (PMID: 34428251)
Cell Cycle. 2012 Nov 1;11(21):3956-63. (PMID: 23082721)
Am J Clin Pathol. 1968 Mar;49(3):347-57. (PMID: 5645095)
F1000Res. 2018 Sep 18;7:. (PMID: 30271576)
Med Oncol. 2013;30(2):577. (PMID: 23609190)
Nutrients. 2022 Mar 04;14(5):. (PMID: 35268056)
Biomed Pharmacother. 2023 Apr;160:114389. (PMID: 36791565)
Proc Natl Acad Sci U S A. 2009 Feb 24;106(8):2859-63. (PMID: 19196965)
BMC Med. 2014 Dec 03;12:224. (PMID: 25465851)
Nat Rev Mol Cell Biol. 2006 Feb;7(2):131-42. (PMID: 16493418)
BJU Int. 2021 Apr;127(4):389-399. (PMID: 32893964)
Endocr Relat Cancer. 2011 Oct 27;18(6):643-55. (PMID: 21859927)
EMBO Rep. 2008 Jun;9(6):582-9. (PMID: 18483486)
Sci Rep. 2017 Sep 20;7(1):11954. (PMID: 28931870)
Cold Spring Harb Perspect Biol. 2017 Apr 3;9(4):. (PMID: 27920038)
Annu Rev Med. 2016;67:137-51. (PMID: 26331999)
Brief Bioinform. 2014 Jan;15(1):1-19. (PMID: 23175680)
Carcinogenesis. 2019 Apr 29;40(2):246-253. (PMID: 30452625)
Oncogene. 2021 Nov;40(44):6284-6298. (PMID: 34584218)
Prostate. 2009 Feb 15;69(3):249-62. (PMID: 18991257)
Oncol Rep. 2017 Jun;37(6):3493-3501. (PMID: 28440476)
فهرسة مساهمة: Keywords: 3-hydroxy-3-methylglutaryl-CoA lyase (HMGCL); Wnt/β-catenin pathway; benign prostate hyperplasia (BPH); epithelial-to-mesenchymal transition (EMT); miR-1202
المشرفين على المادة: 0 (MicroRNAs)
0 (Transforming Growth Factor beta)
EC 4.1.3.4 (3-hydroxy-3-methylglutaryl-coenzyme A lyase)
تواريخ الأحداث: Date Created: 20240329 Date Completed: 20240530 Latest Revision: 20240616
رمز التحديث: 20240616
مُعرف محوري في PubMed: PMC11177111
DOI: 10.3724/abbs.2024001
PMID: 38551020
قاعدة البيانات: MEDLINE
الوصف
تدمد:1745-7270
DOI:10.3724/abbs.2024001